#remestemcel-l

Mesoblast stock hit on gloomy data on stem cells for COVID-19

I’ve been closely following the arena of stem cells for COVID-19 since the pandemic broke including the efforts of Mesoblast. Mesoblast unlikely to meet primary endpoints in Phase III COVID trial Mesoblast CEO Silvio Itescu. Now, the firm got bad news as its DSMB reported that they are unlikely to meet the primary endpoint for their Phase III trial of their stem cell product for COVID-19 based on…

Recommended reads: COVID-19 updates, FDA stem cell nod, PRC2, more

Today’s post is the latest edition of my weekly recommended reads, which this week include Fate Therapeutics, COVID-19 updates, AAMC, and more including some great pubs such as one on 2 modes of PRC2 function.

Fig. 3d Rai et al Nature Communications 2020 “representative images of podosomes by confocal microscopy at 63× magnification. Scale bar 10 μm.”

Also check out this handy resource: Helpful…